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Abstract
Background: We examined racial differences in the expression of eight genes and their associations with risk of
recurrence among 478 white and 495 black women who participated in the Carolina Breast Cancer Study Phase 3.
Methods: Breast tumor samples were analyzed for PAM50 subtype and for eight genes previously found to be
differentially expressed by race and associated with breast cancer survival: ACOX2, MUC1, FAM177A1, GSTT2, PSPH,
PSPHL, SQLE, and TYMS. The expression of these genes according to race was assessed using linear regression and
each gene was evaluated in association with recurrence using Cox regression.
Results: Compared to white women, black women had lower expression of MUC1, a suspected good prognosis
gene, and higher expression of GSTT2, PSPHL, SQLE, and TYMS, suspected poor prognosis genes, after adjustment
for age and PAM50 subtype. High expression (greater than median versus less than or equal to median) of
FAM177A1 and PSPH was associated with a 63% increase (hazard ratio (HR) = 1.63, 95% confidence interval (CI) = 1.
09–2.46) and 76% increase (HR = 1.76, 95% CI = 1.15–2.68), respectively, in risk of recurrence after adjustment for
age, race, PAM50 subtype, and ROR-PT score. Log2-transformed SQLE expression was associated with a 20% increase
(HR = 1.20, 95% CI = 1.03–1.41) in recurrence risk after adjustment. A continuous multi-gene score comprised of
eight genes was also associated with increased risk of recurrence among all women (HR = 1.11, 95% CI = 1.04–1.19)
and among white (HR = 1.14, 95% CI = 1.03–1.27) and black (HR = 1.11, 95% CI = 1.02–1.20) women.
Conclusions: Racial differences in gene expression may contribute to the survival disparity observed between black
and white women diagnosed with breast cancer.
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Background
Historically, white women have had higher incidence rates
of breast cancer compared to black women; however, in
recent years incidence rates among white and black
women have converged [1]. Mortality rates, on the other
hand, remain higher among black women, and rates have
continued to diverge despite notable improvements in sur-
vival in both races since 1990 [2]. Environmental and
other factors including socio-economic status, access to
and quality of care, and delays in treatment have been
cited as potential explanations of the survival disparity, as
have biological factors [3]. Previous research indicates that
even among estrogen receptor (ER)-positive and HER2-
negative breast cancers, which have more favorable
outcomes [4], black women have higher mortality rates
compared to white women [5]. Recent work highlighted
racial differences in risk of recurrence (ROR) scores
among ER+/HER2– breast cancers [6, 7], but biological
differences in tumors between black and white women are
only just beginning to be understood.
Several studies have used whole genome expression data
to screen for racial differences in tumors [8–11], including
our own recent findings [12]. In that study, we examined
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biological differences by race among luminal A and basal-
like breast cancers using publicly available data, and iden-
tified several genes including ACOX2, CRYBB2, MUC1,
PSPH, SQLE, and TYMS that were differentially expressed
by race and that were associated with differences in sur-
vival [12]. A limitation of our prior study was the small
study population, with data from only 108 Caucasian and
57 African-American women. Herein, we expand this ana-
lysis to validate our previous findings in approximately
1000 cases, half of whom are black women, within a larger
population-based context. Specifically, we sought to esti-
mate differences in the expression of two suspected good
prognosis genes (ACOX2 and MUC1) and six suspected
poor prognosis genes (FAM177A1, GSTT2, PSPH, PSPHL,
SQLE, and TYMS) by race, and to examine their associa-
tions with risk of breast cancer recurrence.
Methods
Study population
This study uses data from the Carolina Breast Cancer Study
Phase 3 (CBCS3), a population-based study of 3000 women
conducted in 24 counties in eastern and central North
Carolina from 2008–2013. Recruitment and data collection
procedures for CBCS3 and prior study phases appear else-
where [13]. In brief, women aged 20–74 years residing in
the 24 counties and diagnosed with first primary invasive
breast cancer were identified using rapid case ascertain-
ment in collaboration with the NC Central Cancer Registry.
After determination of study eligibility, sampling was per-
formed to ensure adequate representation of various sub-
groups (i.e., young and African-American women). After
informed consent was obtained, all participants completed
an interviewer-administered questionnaire, provided blood
samples, and provided written consent for retrieval of med-
ical records and paraffin-embedded tumor blocks.
Tumor gene expression profiling and molecular
subtyping
Procedures for tumor gene expression profiling of the
1013 of 3000 women enrolled in the CBCS3 have been
previously published [6]. In brief, RNA was isolated from
cores using the Qiagen RNeasy FFPE kit and protocol,
with 95% of tumors producing quantifiable RNA. The ma-
jority (98.2%) of samples were obtained before neoadju-
vant chemotherapy treatment. Samples were randomized
to batches for RNA extraction and analyses. In total, 1122
samples from 1042 cases from CBCS3 were analyzed for
the PAM50 assay and for the expression of an additional
~150 genes using the NanoString nCounter gene expres-
sion system [14]. The PAM50 predictor [15] was used to
categorize breast tumors into intrinsic subtype as luminal
A, luminal B, HER2-enriched, basal-like, and normal-like,
and to calculate the ROR score with proliferation (ROR-P)
and tumor size (ROR-PT) included. Probes for nine genes
identified by D’Arcy et al. were included: ACOX2,
CRYBB2, MUC1, FAM177A1, GSTT2, PSPH, PSPHL,
SQLE, and TYMS [12].
Quality control was conducted using the NanoString-
Norm package in R. Samples with poor quality were iden-
tified using the following criteria: (1) the ratio of the
geometric mean expression levels of six positive controls
of a sample to the average geometric means of the six
positive controls across all samples fell outside the range
of 0.3–3; (2) the expression level of 90% of endogenous
genes was lower than the mean (+3 SD) of negative con-
trols; and (3) the geometric mean of the reference genes
of a sample was greater than 3 SDs from the average geo-
metric means of the reference genes across all batches. Of
the 1122 samples, 39 did not pass quality control. We fur-
ther excluded 70 duplicate samples with lower quality
gene expression data, resulting in an analytic gene expres-
sion sample of 1013. Of the nine genes of initial interest in
the current study, the expression of one (CRYBB2) was
below the geometric mean of negative controls in > 60% of
samples and was not considered further. The raw RNA
counts were normalized using the geometric mean of the
six positive control genes and then log2-transformed for
analyses. Among the 1013 women with available gene ex-
pression data, we excluded all women who self-identified
as non-black or non-Caucasian white, including seven
American-Indian, 13 Asian, and 20 women of ‘other’
races, resulting in an analytic sample of 478 white and 495
black women (see Additional file 1: Table S1) for partici-
pant characteristics).
Breast cancer recurrence
The time from breast cancer diagnosis to the first breast
cancer recurrence was obtained from the medical re-
cords. Among the 973 women with available gene ex-
pression data, we identified 114 women with at least one
recurrence during a median follow-up of 5.07 years
(range = 0.39–8.22 years). Approximately 9% of white
women and 15% of black women had at least one recur-
rence during the follow-up period.
Statistical analysis
We first examined associations between gene expression
and a range of participant demographics, reproductive fac-
tors, and clinical characteristics using linear regression and
independent sample t tests. Based on likelihood ratio tests
from age-adjusted linear regression models, with the excep-
tion of ER status, there were no significant gene expression-
by-covariate interactions. Therefore, results from the
independent sample t tests based on all women are reported
in Additional file 1: Table S1), and age-adjusted RNA counts
by race and ER status are reported separately in Additional
file 1: Table S2). We then examined race-associated gene
expression of the eight genes overall, and by luminal A and
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basal-like breast cancer subtype using linear regression. In
separate models, we regressed the normalized log2-trans-
formed expression of each of the eight genes on: race (black
vs white), study design variables (age at diagnosis in years,
which was used for sampling; and codeset, which varied be-
tween Nanostring batches), and PAM50 subtype (luminal
A, luminal B, HER2-enriched, basal-like, and normal-like),
as appropriate. The covariate-adjusted β coefficients, repre-
senting the log2(relative difference in gene expression
among black women relative to white women), and the cor-
responding 95% confidence limits from the linear regression
models were back-transformed (i.e., 10(log 10
(2)*β)) to obtain the
relative difference in gene expression.
We dichotomized gene expression at the median (i.e., ≤
median = low, and >median = high expression) for each
gene and, among the 938 women with breast cancer stages
I–III, examined unadjusted associations with risk of recur-
rence using the Kaplan-Meier survival function. Overall,
and by race, and among women with ER+/HER2– breast
cancer, we used Cox regression to estimate hazard ratios
(HRs) and 95% confidence intervals (CIs) for the associa-
tions between dichotomized as well as continuous log2-
transformed gene expression adjusted for age, race, codeset,
PAM50 subtype, and ROR-PT score (low, medium, and
high), as appropriate. Although breast cancer subtype could
potentially mediate the associations between gene expres-
sion and breast cancer recurrence, we were interested in
understanding these adjusted associations rather than as-
suming a causal model. We evaluated the joint effects of all
eight genes on risk of recurrence by creating a multi-gene
race-associated expression (MRE) score. To compute the
score, we applied the method of D’Arcy et al. [12] wherein
we assigned individual scores of –1 or +1 to each of the
eight genes. For six of the eight genes (FAM177A1, GSTT2,
PSPH, PSPHL, SQLE, and TYMS), expression below the
median was assigned a risk score of –1 indicating lower risk
of recurrence, and expression above the median was
assigned a score of +1 indicating higher risk of recurrence.
Given the inverse associations between survival and expres-
sion of ACOX2 and MUC1, for these two genes expression
below the median was assigned a score of +1 and expres-
sion above the median was assigned a score of –1. We
summed the individual gene risk scores resulting in an
MRE score ranging from –8 to +8, with higher scores indi-
cating higher risk of recurrence, and also categorized the
MRE score as –8 to –2 (low), –1 to 3 (medium), and 4 to 8
(high recurrence risk). We conducted all analyses using
SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
Results
In this subsample of women from CBCS3, there were
approximately equal proportions of black (51%) and
white (49%) breast cancer patients (Additional file 1:
Table S1). Women were approximately 52 years of age
on average, and the majority were postmenopausal
(57%), and diagnosed with stage I/II (84%) and grade I/II
(52%) tumors. By PAM50 classification, the majority of
tumors were luminal A (38%), followed by basal-like
(25%), luminal B (20%), HER2-enriched (12%), and
normal-like (5%). As previously reported in CBCS3 [6]
and elsewhere [5, 7], black women of all ages had a
higher frequency of basal-like (33.9% versus 16.7%) and
HER2-enriched (13.3% versus 10.0%) cancers, and lower
frequency of luminal A breast cancers (29.5% versus
47.3%). Few participant demographic and reproductive
factor characteristics were consistently associated with
gene expression. On the other hand, the expression of
most genes was associated with clinicopathological fac-
tors including tumor grade, tumor size, ER and proges-
terone receptor (PR) status, and PAM50 subtype
(Additional file 1: Tables S1 and S2).
Racial differences in gene expression
Overall, black women had lower expression of MUC1, a
good prognosis gene, and higher expression GSTT2,
PSPHL, SQLE, and TYMS, poor prognosis genes, after
adjustment for age, codeset, and PAM50 subtype
(Table 1). The largest difference in expression was for
PSPHL, of which black women had expression levels
that were more than double those in white women (rela-
tive expression = 2.38, 95% CI = 2.11–2.67). Racial pat-
terns in expression of these five genes were similar in
direction and magnitude when restricted to women with
luminal A breast tumors; however, among women with
basal-like tumors, only GSTT2 and PSPHL were differ-
entially expressed by race.
Gene expression and risk of recurrence
As shown in Fig. 1, among stage I–III women of both
races, low (vs high) expression of ACOX2 and MUC1
was associated with increased risk of recurrence (log-
rank χ2 P = 0.015 and P < 0.001, respectively). In con-
trast, high (vs low) expression of PSPH (P = 0.021),
PSPHL (P = 0.001), SQLE (P = 0.012) and TYMS (P <
0.001) were each associated with increased risk of re-
currence. Most associations with recurrence persisted
after adjustment for study design variables (Table 2).
Only FAM177A1, PSPH, and SQLE remained statisti-
cally significant after further adjustment for PAM50
subtype and ROR-PT score. High expression of
FAM177A1 and PSPH was associated with 63% (HR =
1.63, 95% CI = 1.09–2.46) and 76% (HR = 1.76, 95%
CI = 1.15–2.68) increases, respectively, in risk of re-
currence. Dichotomized SQLE expression was not as-
sociated with risk of recurrence; however, continuous
log2-transformed SQLE expression was associated with
a 20% increase (HR = 1.20, 95% CI = 1.03–1.41) in re-
currence risk.
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We next stratified these survival relationships by race.
Patterns of recurrence were similar when adjusting for
study design factors only. However, after further adjust-
ment for PAM50 subtype and ROR-PT score, most asso-
ciations among white women were weaker than those
among black women, with the exception of PSPH which
was stronger in white (HR = 2.04, 95% CI = 1.00–4.15)
than black (HR = 1.69, 95% CI = 1.00–2.85) women.
Among black women, high (vs low) expression of
FAM177A1 was associated with a 73% increase (HR =
1.73, 95% CI = 1.04–2.87) in risk of recurrence in the
fully adjusted model.
Breast cancer mortality disparities are greatest among
women diagnosed with ER+/HER– breast cancer stages
I–III; therefore, we assessed survival associations among
patients with this clinical subtype. In association with
log2-unit increase in expression of MUC1, white women
had reduced risk of recurrence (HR = 0.81, 95% CI =
0.65–1.01), but MUC1 levels were not associated with
recurrence in black women (HR = 0.98, 95% CI = 0.81–
1.20). High (vs low) expression of PSPH and TYMS was
associated with more than twice the risk of recurrence
in black (PSPH HR = 2.25, 95% CI = 0.99–5.13; TYMS
HR = 2.64, 95% CI = 1.00–6.95), but not white (PSPH
HR = 1.90, 95% CI = 0.73–4.95; TYMS HR = 0.51, 95%
CI = 0.19–1.43) women (Additional file 1: Table S3).
The MRE score, which evaluated the additive effects of
all eight genes, was associated with increased risk of re-
currence among all women (HR = 1.11, 95% CI = 1.04–
1.19) and among white (HR = 1.14, 95% CI = 1.03–1.27)
and black (HR = 1.11, 95% CI = 1.02–1.20) women after
covariate adjustment, including adjustment for PAM50
subtype and ROR-PT score. Among women of both
races, the risk of recurrence for women with the highest
MRE scores (4 to 8), relative to those with the lowest
scores (–8 to –2), was associated with a 110% increase
(HR = 2.10, 95% CI = 1.22–3.62) in recurrence risk. In
the subgroup of women with ER+/HER– breast cancer,
the MRE score was associated with a 15% increase in
risk in black women (HR = 1.15, 95% CI = 1.00–1.31),
but not white women (HR = 1.08, 95% CI = 0.95–1.23).
Discussion
Previously reported race and survival-associated genes in-
cluding MUC1, GSTT2, PSPHL, SQLE, and TYMS were
associated with race in this population-based study of
women diagnosed with breast cancer. Except for
FAM177A1 and GSTT2, the genes we examined in this
study were associated with risk of recurrence in un-
adjusted models. Of the genes differentially expressed by
race, SQLE expression as a continuous measure was asso-
ciated with increased risk of breast cancer recurrence,
even after adjustment for breast cancer subtype and ROR
score. Additionally, a multi-gene score comprised of all
eight genes examined in this study was strongly associated
with recurrence risk among all women and among black
women diagnosed with ER+/HER– breast cancer.
Our findings are consistent with prior studies report-
ing lower expression of MUC1 and higher expression of
GSTT2, PSPHL, SQLE, and TYMS among black women
compared to white women [9–12]. MUC1 expression
was positively associated with lower grade, smaller
tumor size, and positive ER/PR status in our study and
in a previous study [16]; however, expression was not as-
sociated with recurrence among black women after ad-
justment for PAM50 subtype, although there was a
suggestive inverse association with recurrence among
white women. MUC1, which is part of a large family of
mucin glycoproteins, is involved with cell signaling and
cell-cell and cell-matrix adhesion [17], and may impact
breast cancer recurrence via these pathways or by dir-
ectly binding to and activating ERα [18]. In contrast to
previous studies, in our study PSPH and ACOX2 were
not differentially expressed by race, although PSPH, but
Table 1 Racial differences in gene expression among white (n = 478) and black (n = 495) women, overall and by breast cancer
subtype, from CBCS Phase 3, 2008–2013
Overall (n = 973) Luminal A (n = 372) Basal-like (n = 248)
Gene Relative expression (95% CI)a P Relative expression (95% CI)a P Relative expression (95% CI)a P
ACOX2 0.99 (0.87–1.12) 0.849 1.00 (0.86–0.96) 0.958 1.12 (0.79–1.58) 0.539
MUC1 0.72 (0.62–0.83) <0.001 0.68 (0.56–0.82) <0.001 0.81 (0.58–1.12) 0.202
FAM177A1 1.00 (0.94–1.06) 0.941 1.00 (0.94–1.07) 0.962 0.98 (0.80–1.20) 0.834
GSTT2 1.41 (1.19–1.68) <0.001 1.43 (1.10–1.85) 0.008 1.58 (1.07–2.32) 0.020
PSPH 1.00 (0.91–1.10) 0.984 0.98 (0.88–1.10) 0.780 1.13 (0.87–1.46) 0.349
PSPHL 2.38 (2.11–2.67) <0.001 2.33 (1.95–2.79) <0.001 1.77 (1.39–2.24) <0.001
SQLE 1.15 (1.04–1.27) 0.007 1.19 (1.05–1.35) 0.006 0.98 (0.76–1.27) 0.868
TYMS 1.20 (1.11–1.29) <0.001 1.24 (1.12–1.38) <0.001 1.08 (0.92–1.26) 0.345
RNA counts were normalized log2-transformed prior to analysis
CI confidence interval
aRelative expression comparing black versus white (referent) women; relative expression is adjusted for age, codeset, and PAM50 subtype, as appropriate
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not ACOX2, expression was associated with recurrence.
Interestingly, recent evidence suggests that racial differ-
ences in the expression of PSPHL may be a consequence
of a 30-kb deletion from chromosome 7p11, including
the promoter and first three of four exons of PSPHL, ef-
fectively eliminating PSPHL expression, more frequently
found among individuals of African ancestry [19]. Al-
though we did not examine PSPHL polymorphisms, our
findings may reflect underlying genetic differences.
Whereas the study by Rummel and colleagues [19]
found no association between PSPHL loss or retention
and pathological characteristics, in our study, PSPHL ex-
pression was associated with grade, tumor size, ER/PR
status, and breast cancer PAM50 subtype [19].
SQLE expression was higher in tumors of black women
compared to white women, and was associated with more
Fig. 1 Risk of recurrence by dichotomized gene expression (dashed line = expression below median; solid line = expression above median) from
CBCS Phase 3, 2008–2013 (n = 938). a Genes previously found to be inversely associated with breast cancer mortality, and b genes previously
found to be positively associated with breast cancer mortality
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Table 2 Gene expression and risk of recurrence, overall and by race, from CBCS Phase 3, 2008–2013
Overall (n = 938) White (n = 465) Black (n = 473)
Gene Recurrence/n HRb (95% CI) HRc (95% CI) Recurrence/n HRb (95% CI) HRc (95% CI) Recurrence/n HRb (95% CI) HRc (95% CI)
ACOX2
≤Median 66/469 1.00 1.00 25/206 1.00 1.00 41/263 1.00 1.00
> Median 45/469 0.65
(0.44–0.96)
0.88
(0.58–1.32)
17/259 0.44
(0.24–0.83)
0.68
(0.35–1.32)
28/210 0.84
(0.51–1.37)
1.09
(0.65–1.82)
Log2 0.94
(0.83–1.06)
1.05
(0.93–1.18)
0.81
(0.64–1.01)
0.99
(0.79–1.23)
1.01
(0.88–1.17)
1.09
(0.95–1.25)
MUC1
≤Median 72/474 1.00 1.00 24/179 1.00 1.00 48/295 1.00 1.00
> Median 39/464 0.57
(0.38–0.85)
0.89
(0.57–1.40)
18/286 0.38
(0.21–0.71)
0.62
(0.30–1.26)
21/178 0.71
(0.43–1.19)
1.04
(0.58–1.86)
Log2 0.87
(0.79–0.95)
0.97
(0.87–1.08)
0.77
(0.67–0.88)
0.88
(0.74–1.04)
0.93
(0.83–1.05)
1.02
(0.89–1.18)
FAM177A1
≤Median 47/468 1.00 1.00 16/211 1.00 1.00 31/257 1.00 1.00
> Median 64/470 1.32
(0.89–1.95)
1.63
(1.09–2.46)
26/254 1.05
(0.53–2.06)
1.37
(0.69–2.73)
38/216 1.44
(0.89–2.35)
1.73
(1.04–2.87)
Log2 1.14
(0.86–1.50)
1.33
(1.01–1.73)
1.14
(0.68–1.92)
1.46
(0.90–2.39)
1.14
(0.81–1.59)
1.28
(0.92–1.77)
GSTT2
≤Median 51/471 1.00 1.00 22/250 1.00 1.00 29/221 1.00 1.00
> Median 60/467 1.06
(0.72–1.55)
1.27
(0.86–1.88)
20/215 0.97
(0.53–1.78)
1.26
(0.68–2.34)
40/252 1.18
(0.72–1.93)
1.36
(0.82–2.26)
Log2 1.01
(0.92–1.11)
1.07
(0.97–1.18)
0.96 (0.82–1.12) 1.03 (0.88–1.20) 1.06
(0.93–1.20)
1.11
(0.97–1.26)
PSPH
≤Median 41/472 1.00 1.00 13/228 1.00 1.00 28/244 1.00 1.00
> Median 70/466 1.71
(1.12–2.61)
1.76
(1.15–2.68)
29/237 1.79
(0.87–3.71)
2.04
(1.00–4.15)
41/229 1.66
(0.98–2.80)
1.69
(1.00–2.85)
Log2 1.18
(1.00–1.41)
1.18
(1.00–1.39)
1.32
(0.95–1.84)
1.36
(0.98–1.87)
1.15
(0.94–1.40)
1.14
(0.94–1.38)
PSPHL
≤Median 40/474 1.00 1.00 25/341 1.00 1.00 15/133 1.00 1.00
> Median 71/464 1.52
(0.95–2.44)
1.33
(0.83–2.15)
17/124 1.74
(0.93–3.26)
1.53
(0.80–2.92)
54/340 1.42
(0.72–2.81)
1.24
(0.62–2.48)
Log2 1.14
(1.00–1.31)
1.09
(0.95–1.26)
1.19
(0.96–1.48)
1.10
(0.87–1.39)
1.16
(0.97–1.38)
1.10
(0.92–1.32)
SQLE
≤Median 41/468 1.00 1.00 17/273 1.00 1.00 24/195 1.00 1.00
> Median 70/470 1.47
(0.99–2.17)
1.09
(0.73–1.64)
25/192 1.97
(1.06–3.65)
1.40
(0.72–2.72)
45/278 1.23
(0.75–2.03)
0.96
(0.58–1.60)
Log2 1.31
(1.13–1.52)
1.20
(1.03–1.41)
1.40
(1.09–1.80)
1.21
(0.91–1.59)
1.27
(1.06–1.53)
1.19
(0.98–1.44)
TYMS
≤Median 35/469 1.00 1.00 19/282 1.00 1.00 16/187 1.00 1.00
> Median 76/469 1.93
(1.27–2.92)
1.11
(0.67–1.84)
23/183 1.70
(0.91–3.18)
0.65
(0.29–1.47)
53/286 2.09
(1.18–3.68)
1.50
(0.77–2.90)
Log2 1.37
(1.15–1.64)
1.04
(0.83–1.30)
1.38
(1.02–1.85)
0.84
(0.61–1.15)
1.34
(1.06–1.69)
1.08
(0.80–1.46)
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aggressive tumors including tumors of high histologic
grade, nodal involvement, larger size, ER–/HER2+ status,
and with increased risk of breast cancer recurrence, consist-
ent with prior studies [20]. Applying the criteria proposed
by D’Arcy et al. [12] for a disparity-associated gene that: (1)
the gene should be differentially expressed by race in the
tumor, and (2) the differential expression of a candidate
gene should be associated with a difference in breast cancer
survival, we identified SQLE as a disparity-associated gene.
SQLE is located on chromosome 8q24.13, and encodes
squalene epoxidase, an enzyme that catalyzes the first oxy-
genation step in cholesterol synthesis [21]. Given that squa-
lene epoxidase is thought to be one of the rate-limiting
enzymes in the cholesterol synthesis pathway, overexpres-
sion of SQLE may also result in increased cholesterol bio-
availability, which may promote ER-dependent growth and
Liver X receptor-dependent metastasis [22]. Furthermore,
as prior researchers have hypothesized [20], SQLE expres-
sion together with overexpression of other nearby genes in-
cluding RAD21, which encodes a protein involved in DNA
repair, could work to promote a more aggressive cancer
phenotype. If SQLE is confirmed by other studies, these
findings provide further evidence for the potential use of
statins in adjuvant breast cancer therapy [23, 24] as well as
the potential for SQLE inhibition as a novel cancer treat-
ment option [20]. The function of FAM177A1 (family with
sequence similarity 177 member A1) [25] and PSPHL
(phospherine phosphatase-like) [26] are not well character-
ized and thus their associations with recurrence are not en-
tirely clear. PSPHL is hypothesized to influence rates of
cellular proliferation [27], and therefore could potentially
directly impact cancer progression.
This study had several strengths including the large
population-based design including the oversampling of
young and black women; however, this study had several
limitations. First, in our analyses of breast cancer
recurrence, the proportion of women with at least one re-
currence was relatively small (10%); however, ours is the lar-
gest study conducted to date on the topic and provides
results consistent with previous studies. Second, a limita-
tion of this research is that we cannot establish the mech-
anism for higher expression levels (i.e., we cannot
distinguish between expression changes that are due to dif-
ferentiation state or cell lineage versus those that are due to
tumor-specific mutations). We also note that some of the
genes had prognostic value only within one subtype. For
example, genes that tend to be strongly associated with pro-
liferation, such as MUC1 and TYMS, tended to have more
prognostic value among luminal breast cancers where pro-
liferation status is variable; very few basal-like breast can-
cers have low proliferation and therefore proliferation
genes often do not provide prognostic value. Third, given
prior reports of higher expression of CRYBB2 among black
women compared with white women [7–9, 11, 12], we were
a priori interested in including CRYBB2 in our analyses; un-
fortunately, we were unable to examine expression of this
gene due to a large amount of missing data. Future studies
should continue to examine CRYBB2 expression for its po-
tential relevance as a disparity-associated gene. Finally, in
this study we did not compare gene expression in tumor
tissue to normal or adjacent-normal tissue; however, in our
previous work [12] we observed that patterns of expression,
comparing normal to tumor, were similar between black
and white women. This suggests that differences in cellular
composition between black and white women are not re-
sponsible for the racial differences inMUC1 expression.
Conclusions
In summary, we validated previously observed racial dif-
ferences in the expression of several genes using a large
population-based study. Of the genes that were differen-
tially expressed by race, high expression of one gene,
Table 2 Gene expression and risk of recurrence, overall and by race, from CBCS Phase 3, 2008–2013 (Continued)
Overall (n = 938) White (n = 465) Black (n = 473)
Gene Recurrence/n HRb (95% CI) HRc (95% CI) Recurrence/n HRb (95% CI) HRc (95% CI) Recurrence/n HRb (95% CI) HRc (95% CI)
MRE Scorea
–8 to –2 25/367 1.00 1.00 9/207 1.00 1.00 16/160 1.00 1.00
–1 to 3 36/336 1.48
(0.88–2.48)
1.14
(0.67–1.94)
16/169 1.93
(0.83–4.47)
1.67
(0.72–3.85)
20/167 1.18
(0.61–2.30)
0.88
(0.44–1.76)
4 to 8 50/235 3.03
(1.80–5.07)
2.10
(1.22–3.62)
17/89 4.42
(1.89–10.32)
2.88
(1.17–7.11)
33/146 2.44
(1.29–4.62)
1.78
(0.91–3.49)
Trend 1.15
(1.09–1.22)
1.11
(1.04–1.19)
1.19
(1.08–1.31)
1.14
(1.03–1.27)
1.14
(1.05–1.23)
1.11
(1.02–1.20)
RNA counts were normalized log2-transformed prior to analysis; analyses exclude women with unknown stage and stage IV breast cancer
Log2 = continuous normalized log2-transformed gene expression
CI confidence interval, HR hazard ratio
aMulti-gene race-associated expression (MRE) score based on eight genes with higher scores indicating worse risk or recurrence: for ACOX2 and MUC1, ≤ median
= 1 vs >median = –1; for FAM177A1, GSTT2, PSPH, PSPHL, SQLE, and TYMS, ≤ median = –1 vs >median = 1
bAdjusted for age, race (black vs. white), and codeset, as appropriate
cAdjusted for age, race (black vs. white), codeset, PAM50 subtype (luminal A, luminal B, HER2-enriched, basal-like, or normal-like), and risk of recurrence score with
tumor size (ROR-PT; low, medium, or high), as appropriate
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SQLE, was also associated with an increased risk of
breast cancer recurrence and thus may be a potential
disparity-associated gene. Among women with the more
favorable ER+/HER2– breast cancer subtype, the multi-
gene race-associated score comprised of all eight genes
was associated with a 15% increase in risk of recurrence
among black but not white women. We conclude that
racial differences in gene expression may contribute to
the survival disparity observed between black and white
women diagnosed with breast cancer.
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